BACKGROUND:Children with moderate acute malnutrition (MAM) are often treated with fortified blended flours, most commonly a corn-soy blend (CSB). However, recovery rates remain <75%, lower than the rate achieved with peanut paste-based ready-to-use supplementary foods (RUSFs). To bridge this gap, a novel CSB recipe fortified with oil and dry skim milk, "CSB++," has been developed. OBJECTIVE: In this trial we compared CSB++ with 2 RUSF products for the treatment of MAM to test the hypothesis that the recovery rate achieved with CSB++ will not be >5% worse than that achieved with either RUSF. DESIGN: We conducted a prospective, randomized, investigator-blinded, controlled noninferiority trial involving rural Malawian children aged 6-59 mo with MAM. Children received 75 kcal CSB++ · kg(-1) · d(-1), locally produced soy RUSF, or an imported soy/whey RUSF for ≤12 wk. RESULTS: The recovery rate for CSB++ (n = 763 of 888; 85.9%) was similar to that for soy RUSF (795 of 806, 87.7%; risk difference: -1.82%; 95% CI: -4.95%, 1.30%) and soy/whey RUSF (807 of 918, 87.9%; risk difference: -1.99%; 95% CI: -5.10%, 1.13%). On average, children who received CSB++ required 2 d longer to recover, and the rate of weight gain was less than that with either RUSF, although height gain was the same among all 3 foods studied. CONCLUSIONS: A novel, locally produced, fortified blended flour (CSB++) was not inferior to a locally produced soy RUSF and an imported soy/whey RUSF in facilitating recovery from MAM. The recovery rate observed for CSB++ was higher than that for any other fortified blended flour tested previously. This trial is registered at clinicaltrials.gov as NCT00998517.
RCT Entities:
BACKGROUND:Children with moderate acute malnutrition (MAM) are often treated with fortified blended flours, most commonly a corn-soy blend (CSB). However, recovery rates remain <75%, lower than the rate achieved with peanut paste-based ready-to-use supplementary foods (RUSFs). To bridge this gap, a novel CSB recipe fortified with oil and dry skim milk, "CSB++," has been developed. OBJECTIVE: In this trial we compared CSB++ with 2 RUSF products for the treatment of MAM to test the hypothesis that the recovery rate achieved with CSB++ will not be >5% worse than that achieved with either RUSF. DESIGN: We conducted a prospective, randomized, investigator-blinded, controlled noninferiority trial involving rural Malawian children aged 6-59 mo with MAM. Children received 75 kcal CSB++ · kg(-1) · d(-1), locally produced soy RUSF, or an imported soy/whey RUSF for ≤12 wk. RESULTS: The recovery rate for CSB++ (n = 763 of 888; 85.9%) was similar to that for soy RUSF (795 of 806, 87.7%; risk difference: -1.82%; 95% CI: -4.95%, 1.30%) and soy/whey RUSF (807 of 918, 87.9%; risk difference: -1.99%; 95% CI: -5.10%, 1.13%). On average, children who received CSB++ required 2 d longer to recover, and the rate of weight gain was less than that with either RUSF, although height gain was the same among all 3 foods studied. CONCLUSIONS: A novel, locally produced, fortified blended flour (CSB++) was not inferior to a locally produced soy RUSF and an imported soy/whey RUSF in facilitating recovery from MAM. The recovery rate observed for CSB++ was higher than that for any other fortified blended flour tested previously. This trial is registered at clinicaltrials.gov as NCT00998517.
Authors: P G Miotti; T E Taha; N I Kumwenda; R Broadhead; L A Mtimavalye; L Van der Hoeven; J D Chiphangwi; G Liomba; R J Biggar Journal: JAMA Date: 1999-08-25 Impact factor: 56.272
Authors: Monika Grillenberger; Charlotte G Neumann; Suzanne P Murphy; Nimrod O Bwibo; Pieter van't Veer; Joseph G A J Hautvast; Clive E West Journal: J Nutr Date: 2003-11 Impact factor: 4.798
Authors: Jonathan H Siekmann; Lindsay H Allen; Nimrod O Bwibo; Montague W Demment; Suzanne P Murphy; Charlotte G Neumann Journal: J Nutr Date: 2003-11 Impact factor: 4.798
Authors: Owen W W Nkhoma; Maresa E Duffy; Deborah A Cory-Slechta; Philip W Davidson; Emeir M McSorley; J J Strain; Gerard M O'Brien Journal: J Nutr Date: 2013-06-26 Impact factor: 4.798
Authors: Jai K Das; Rehana A Salam; Yousaf Bashir Hadi; Sana Sadiq Sheikh; Afsah Z Bhutta; Zita Weise Prinzo; Zulfiqar A Bhutta Journal: Cochrane Database Syst Rev Date: 2019-05-02
Authors: Brie Falkard; T R Santha Kumar; Leonie-Sophie Hecht; Krista A Matthews; Philipp P Henrich; Sonia Gulati; Rebecca E Lewis; Micah J Manary; Elizabeth A Winzeler; Photini Sinnis; Sean T Prigge; Volker Heussler; Christina Deschermeier; David Fidock Journal: Cell Microbiol Date: 2013-04-05 Impact factor: 3.715